Skip to content
Tirzepatide 10mg Easy Pen
Tirzepatide 10mg Easy Pen - Image 2
Tirzepatide 10mg Easy Pen - Image 3

Tirzepatide 10mg Easy Pen

$360

  • EP-TIR-10-1

In stock

Specifications: 

  • 0.05mg per click.
  • Up to 60 clicks per dose.
  • Includes 4 needles and one adjustable dosage pre-mixed pen.

Tirzepatide: Dual Hormone Fat & Sugar Fighter

High-Efficacy Weight Loss, Glucose Balance, Heart & Liver Protection

Tirzepatide is a promising groundbreaking dual agonist that activates both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptors by combining two powerful metabolic pathways in one injectable therapy. This unique “twincretin” approach offers amplified potential benefits, including dramatic weight reduction, improved insulin sensitivity, enhanced fat and liver metabolism, and protection of cardiovascular and kidney health in multiple ongoing studies.

Clinically, tirzepatide has demonstrated results in initial studies beyond traditional GLP-1 therapies, achieving up to 20%+ body weight loss, major HbA1c reductions, and robust cardiometabolic improvements. It’s a promising potent, multi-system metabolic reset ideal for research on patients focused on comprehensive metabolic wellness.

Research on Tirzepatide as a dual GIP/GLP-1 receptor agonist shows promising results:

  • GIP receptor activation enhances meal-induced insulin secretion and promotes fat metabolism.
  • GLP-1 receptor activation improves glucose control, induces satiety, and delays gastric emptying.
  • Combined, these mechanisms suppress hunger, stabilize blood sugar, burn fat (even without extra exercise), and protect metabolic organs like the heart and liver.

Key Potential Benefits

  • Exceptional Weight Loss – In SURMOUNT‑1, up to 20.9% body weight reduction at 72 weeks (15 mg dose); most users lose ≥20%.
  • Superior Glycemic Control – Dose-dependent HbA1c drops in diabetes, outperforming GLP‑1-only agents.
  • Visceral & Liver Fat Reduction – Significant reductions in abdominal adiposity and liver fat, improving NAFLD/MASLD biomarkers.
  • Cardiovascular & Heart Failure Support – 38% lower risk of hospitalization/death in HFpEF; favorable impact on MACE and lipid markers.
  • Kidney & All-Cause Mortality Benefits – Observational studies show reduced risk of major cardiovascular events, kidney outcomes, and death.
  • Improved Lipid Panel – Dropped total cholesterol, LDL, and triglycerides while raising HDL.
  • Lean Mass Preservation – Rapid fat loss without sacrificing muscle mass or metabolic rate.
  • Appetite Suppression & Satiety Support – Dual-hormone action increases fullness while reducing cravings and lowering calorie intake.

Technical Information
CAS Number:
2023788-19-2
PubChem CID:
163285896
Formula:
C227H352N48O70
Synonyms:
TZP, Tirzepatide Acetate, AKOS040763900, TS-10296, Tirzepatide Acetate (2023788-19-2 free base)